Clinical Trial Update: Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 trial update examining whether linagliptin rapidly modulates monocyte polarization and endothelial progenitor cells in people with type 2 diabetes, in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (Tradjenta) (linagliptin)

Snippet

Sponsor: University of Padova | Conditions: Type 2 Diabetes, Chronic Renal Failure | Phase 4 | Status: COMPLETED